TY - JOUR
T1 - Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk
T2 - Multicenter Randomized Trial CROSS-J-RCC
AU - Tomita, Yoshihiko
AU - Naito, Sei
AU - Sassa, Naoto
AU - Takahashi, Atsushi
AU - Kondo, Tsunenori
AU - Koie, Takuya
AU - Obara, Wataru
AU - Kobayashi, Yasuyuki
AU - Teishima, Jun
AU - Takahashi, Masayuki
AU - Matsuyama, Hideyasu
AU - Ueda, Takeshi
AU - Yamaguchi, Kenya
AU - Kishida, Takeshi
AU - Shiroki, Ryoichi
AU - Saika, Takashi
AU - Shinohara, Nobuo
AU - Oya, Mototsugu
AU - Kanayama, Hiro omi
N1 - Funding Information:
Y.T. has received grants and lecture and advisory fees from Novartis, Japan; Ono, and Astellas, grants and lecture fees from Astellas and Pfizer, Japan lecture fees from Bristol-Myers Squibb, Japan and grants from Takeda, Japan. T. Kondo has received lecture fees from Intuitive Surgical, Novartis, Ono, and Pfizer. W.O. has received grants form Nipuro and Takeda and lecture fees from Astellas, Bristol-Myers Squibb, Ono, and Pfizer. J.T. has received lecture fees from Pfizer. M.T. has received lecture fees from Pfizer. H.M. has received grants and lecture fees from Janssen, grants from Kyowa-Hakko-Kirin, Japan;Merck biopharma, Japan; Sharp & Dohme, Takeda Terumo, and Toyo Steel. R.S. has received lecture fees from Intuitive Surgical and Novartis and a grant from Astellas. T.S. has received grants and lecture fees from Astellas and Takeda and lecture fees from Novartis. N. Shinohara has received grants and lecture fees from Astellas and Ono, lecture fees from Bayer, and lecture fees from Bayer, GlaxoSmithKline, Pfizer, and Takeda. M.O. has received grants and lecture fees from Pfizer and lecture fees from Bayer, Bristol-Myers Squibb, Novartis, and Ono. H.K. has received grant and lecture fees from Pfizer and grants from Astellas, Ono, Sanofi, Japan; Taiho, and Takeda. The remaining authors declare that they have no competing interests.The present study was supported in part by the Japanese Urological Research Network and Pfizer. The authors would like to thank Enago (www.enago.jp) for the English language review.
Funding Information:
Y.T. has received grants and lecture and advisory fees from Novartis , Japan; Ono , and Astellas , grants and lecture fees from Astellas and Pfizer , Japan lecture fees from Bristol-Myers Squibb , Japan and grants from Takeda, Japan . T. Kondo has received lecture fees from Intuitive Surgical, Novartis, Ono, and Pfizer. W.O. has received grants form Nipuro and Takeda and lecture fees from Astellas, Bristol-Myers Squibb, Ono, and Pfizer. J.T. has received lecture fees from Pfizer. M.T. has received lecture fees from Pfizer. H.M. has received grants and lecture fees from Janssen , grants from Kyowa-Hakko-Kirin , Japan; Merck biopharma , Japan; Sharp & Dohme , Takeda Terumo , and Toyo Steel . R.S. has received lecture fees from Intuitive Surgical and Novartis and a grant from Astellas . T.S. has received grants and lecture fees from Astellas and Takeda and lecture fees from Novartis. N. Shinohara has received grants and lecture fees from Astellas and Ono , lecture fees from Bayer, and lecture fees from Bayer, GlaxoSmithKline, Pfizer, and Takeda. M.O. has received grants and lecture fees from Pfizer and lecture fees from Bayer, Bristol-Myers Squibb, Novartis, and Ono. H.K. has received grant and lecture fees from Pfizer and grants from Astellas , Ono , Sanofi , Japan; Taiho , and Takeda . The remaining authors declare that they have no competing interests.
Publisher Copyright:
© 2020 The Authors
PY - 2020/8
Y1 - 2020/8
N2 - The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).
AB - The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).
UR - http://www.scopus.com/inward/record.url?scp=85085351126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085351126&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2020.01.001
DO - 10.1016/j.clgc.2020.01.001
M3 - Article
C2 - 32466961
AN - SCOPUS:85085351126
VL - 18
SP - e374-e385
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 4
ER -